Blog

ADELAIDE, AU / ACCESS Newswire / July 28, 2025 / Barton Gold Holdings Limited (ASX:BGD)(FRA:BGD3)(OTCQB:BGDFF) ( Barton or Company ) advises that the Quarterly Activities and Cashflow Report for the quarter ended 30 June 2025 has been released to the market.

These reports can be accessed directly via the following links:

• Quarterly Activities Report

• Quarterly Cashflow Report

Authorised by the Managing Director of Barton Gold Holdings Limited.

For further information, please contact:

About Barton Gold

Barton Gold is an ASX, OTCQB and Frankfurt Stock Exchange listed Australian gold developer targeting future gold production of 150,000ozpa with 2.1Moz Au & 3.1Moz Ag JORC Mineral Resources (78.9Mt @ 0.85 g/t Au), brownfield mines, and 100% ownership of the region’s only gold mill in the renowned Gawler Craton of South Australia.*

Competent Persons Statement & Previously Reported Information

The information in this announcement that relates to the historic Exploration Results and Mineral Resources as listed in the table below is based on, and fairly represents, information and supporting documentation prepared by the Competent Person whose name appears in the same row, who is an employee of or independent consultant to the Company and is a Member or Fellow of the Australasian Institute of Mining and Metallurgy ( AusIMM ), Australian Institute of Geoscientists ( AIG ) or a Recognised Professional Organisation (RPO). Each person named in the table below has sufficient experience which is relevant to the style of mineralisation and types of deposits under consideration and to the activity which he has undertaken to quality as a Competent Person as defined in the JORC Code 2012 ( JORC ).

The information relating to historic Exploration Results and Mineral Resources in this announcement is extracted from the Company’s Prospectus dated 14 May 2021 or as otherwise noted in this announcement, available from the Company’s website at www.bartongold.com.au or on the ASX website www.asx.com.au . The Company confirms that it is not aware of any new information or data that materially affects the Exploration Results and Mineral Resource information included in previous announcements and, in the case of estimates of Mineral Resources, that all material assumptions and technical parameters underpinning the estimates, and any production targets and forecast financial information derived from the production targets, continue to apply and have not materially changed. The Company confirms that the form and context in which the applicable Competent Persons’ findings are presented have not been materially modified from the previous announcements.

Cautionary Statement Regarding Forward-Looking Information

This document may contain forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “expect”, “target” and “intend” and statements than an event or result “may”, “will”, “should”, “would”, “could”, or “might” occur or be achieved and other similar expressions. Forward-looking information is subject to business, legal and economic risks and uncertainties and other factors that could cause actual results to differ materially from those contained in forward-looking statements. Such factors include, among other things, risks relating to property interests, the global economic climate, commodity prices, sovereign and legal risks, and environmental risks. Forward-looking statements are based upon estimates and opinions at the date the statements are made. Barton undertakes no obligation to update these forward-looking statements for events or circumstances that occur subsequent to such dates or to update or keep current any of the information contained herein. Any estimates or projections as to events that may occur in the future (including projections of revenue, expense, net income and performance) are based upon the best judgment of Barton from information available as of the date of this document. There is no guarantee that any of these estimates or projections will be achieved. Actual results will vary from the projections and such variations may be material. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. Any reliance placed by the reader on this document, or on any forward-looking statement contained in or referred to in this document will be solely at the readers own risk, and readers are cautioned not to place undue reliance on forward-looking statements due to the inherent uncertainty thereof.

* Refer to Barton Prospectus dated 14 May 2021 and ASX announcement dated 25 July 2025. Total Barton JORC (2012) Mineral Resources include 1,049koz Au (39.7Mt @ 0.82 g/t Au) in Indicated category and 1,095koz Au (39.2Mt @ 0.87 g/t Au) in Inferred category, and 3,070koz Ag (34.5Mt @ 2.80 g/t Ag) in Inferred category as a subset of Tunkillia gold JORC (2012) Mineral Resources.

SOURCE: Barton Gold Holdings Limited

View the original press release on ACCESS Newswire

VANCOUVER, BC AND BREDA, THE NETHERLANDS / ACCESS Newswire / July 28, 2025 / Organto Foods Incorporated (TSX-V:OGO)(OTC:OGOFF) (“Organto” or the “Company”) (“Organto” or the “Company”) is pleased to announce the appointment of Mr. Javier Reyes de la Campa as Co-Chair of the Board of Directors, alongside Steve Bromley, effective immediately.

Javier Reyes de la Campa is a seasoned professional and entrepreneur with over 25 years of experience in investing and building companies. He has co-founded various firms across the finance, mining, agriculture and food sectors. More recently, his strategic leadership was instrumental in the strategic turnaround of Luca Mining Corporation, a producing company with assets in Mexico. Luca Mining Corporation was recently named to the 2025 Toronto Stock Exchange Venture 50™ list of top-performing companies. Mr. Reyes de la Campa was a founding director of Organto Foods and previously served on the Board of Directors from 2015 through 2020. An alumnus of Harvard Business School, Mr. Reyes de la Campa holds dual bachelor’s degrees in economics and business administration, as well as a master’s degree in finance from the Instituto Tecnológico Autónomo de México.

Steve Bromley, Chief Executive Officer and Co-Chair of Organto Foods, commented: “We are thrilled to welcome Javier as Co-Chair. His strategic insight, leadership experience, and international perspective will be invaluable as we continue to grow our platform and meet the increasing global demand for organic and responsibly sourced food products. Javier joins us at an optimal time, as the we are accelerating our growth and profitability as well as widening our product offering.”

Javier Reyes de la Campa, Co-Chairman, added: “I am honored and excited to join Organto’s Board of Directors at this exciting time for the Company. I admire the hard work of Steve and the entire team over the past eighteen months to reposition the Company for success. The Company’s mission to make healthy, organic foods more accessible and its dedication to sustainable business practices align closely with my own values. I look forward to working alongside the Board of Directors and management team to unlock the Company’s full potential and maximize shareholder value.”

Grant of Stock Options and Restricted Share Units

The Company also announces that it has granted 125,000 stock options to certain employees as per the terms of the Company’s Share Option Plan. The options were granted at an exercise price of $0.54 per share and have a term of five years. The options issued will vest 20% immediately and 20% on each anniversary thereafter. In addition, 1,000,000 restricted stock units were issued to certain directors of the Company as per the terms of the Company’s Restricted Share Unit Plan. The restricted share units have a term of 3 years and will vest one-third after one-year and one-third every six months thereafter.

ON BEHALF OF THE BOARD

Steve Bromley
Co-Chair and CEO

For more information, contact:
Investor Relations
John Rathwell, Senior Vice President, Corporate Development
647 629 0018
info@organto.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

ABOUT ORGANTO

Organto is a leading provider of branded, private label, and distributed organic and non-GMO fruit and vegetable products using a strategic asset-lighter business model to serve a growing socially responsible and health-conscious consumers. Organto’s business model is rooted in its commitment to sustainable business practices focused on environmental responsibility and a commitment to the communities where it operates, its people, and its shareholders.

FORWARD LOOKING STATEMENTS

This news release may include certain forward-looking information and statements, as defined by law, including without limitation, Canadian securities laws and the “safe harbor” provisions of the US Private Securities Litigation Reform Act (“forward-looking statements”). In particular, and without limitation, this news release contains forward-looking statements respecting the Company’s belief that Mr. Reyes de la Campa’s insight, leadership experience and international perspective will be invaluable as the Company grows its platform focused on meeting global demand for organic and responsibly sourced food products and the Company’s belief that Mr. Reyes de la Campa is joining at an optimal time as the Company is accelerating its growth and profitability and widening it product offering. Forward-looking statements are based on a number of assumptions that may prove to be incorrect, including, without limitation, the assumption that Mr. Reyes de la Campa joining the Board of Directors as Co-Chair is a positive development for the Company. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in forward-looking statements in this news release include, among others, uncertainty regarding the regulatory risks; risks related to market volatility and economic conditions; risks related to unforeseen delays; and risks that necessary financing will be unavailable when needed. For further information on these and other risks and uncertainties that may affect the Company’s business, see the “Risks and Uncertainties” and “Forward-Looking Statements” sections of the Company’s annual and interim management’s discussion and analysis filings with the Canadian securities regulators, which are available under the Company’s profile at www.sedarplus.ca. Except as required by law, Organto does not assume any obligation to release publicly any revisions to forward-looking statements contained in this news release to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE: Organto Foods, Inc.

View the original press release on ACCESS Newswire

AUSTIN, TX / ACCESS Newswire / July 29, 2025 / Thermon Group Holdings, Inc. (NYSE:THR) (“Thermon”), a global leader in thermal management, power distribution, and environmental controls, today announced its universal availability of their new Poseidon™ Liquid Load Bank (for US markets) and Pontus™ Liquid Load Bank (for non-US markets). These advanced systems are designed to accurately simulate real-world thermal and electrical demand, providing mission critical component test validation for data centers and other High Performance Computing (HPC) environments.

The new liquid load banks offer a built-for-purpose solution for the rigorous demands of data center commissioning and start up. They serve as essential test validation systems for critical HPC data center infrastructure, like Coolant Distribution Units, Uninterruptible Power Supplies and back-up power generators.

Key features and benefits of the Poseidon and Pontus Load Banks include:

• A built-for-purpose liquid-cooled load bank targeting the data center commissioning and start-up market, including Integrated Systems Testing.

• Industry-leading performance, sizing, and weight, contributing to the lower total cost of ownership.

• Engineered for data center testing applications – with integrated modern controls and monitoring in a standardized package for quick delivery.

• Simple, easy controls and a comprehensive audible alarm system to indicate high temperature, low flow, and low water conditions.

• Modular design with the ability to connect over 100 units in series to test the increasing IT loads in the industry.

Custom designed and optimized by process heating/heat transfer experts, but standardized for quicker lead times and more value, the Poseidon and Pontus Load Banks boast a robust capacity rating up to 600kW within a compact design. Built for rapid deployment, these lightweight systems feature a mobile, space-saving design, allowing for quick and efficient testing in different locations within modular, mobile HPC and other data center environments.

Poseidon and Pontus load banks provide real-time oversight of the dynamic thermal performance and electrical demands crucial for a modern data center in the rapidly expanding age of artificial intelligence (AI).

“The launch of the Poseidon and Pontus Liquid Load Banks marks a significant milestone for Thermon – greatly expanding our opportunity within the rapidly growing data center market.” said Bruce Thames, President & CEO of Thermon. “As data centers evolve to meet the intense demands of AI and HPC, the need for precise, reliable, and efficient validation tools is paramount. Our new liquid load banks deliver unparalleled performance, mobility, and ease of use, reinforcing Thermon’s commitment to providing innovative solutions that empower our customers to build and operate the most robust and efficient critical infrastructure.”

The new liquid load banks are available globally and are certified to local requirements along with the following applicable standards: UL, CSA, CE, ASME, ANSI, NEMA, PED and NEC, ensuring compliance and reliability across diverse markets.

For more information on the Poseidon and Pontus load banks, click here.

Through its global network, Thermon provides safe, reliable and mission critical industrial process heating solutions. Thermon specializes in providing complete flow assurance, process heating, temperature maintenance, freeze protection and environmental monitoring solutions. Thermon is headquartered in Austin, Texas. For more information, please visit www.thermon.com.

CONTACT:
Michelle Saab,
Senior Manager, Global Marketing
Phone: +1-512-560-5482

SOURCE: Thermon Group Holdings Inc.

View the original press release on ACCESS Newswire

Oral, non-opioid drug candidate advancing through Phase 1 and nearing completion of the single ascending dose (SAD) portion as the Company prepares to launch U.S. Phase 2a by year-end

MIAMI, FLORIDA / ACCESS Newswire / July 29, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company developing novel therapies for neurologic, neuropsychiatric, and metabolic disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Ketamir-2, a novel oral NMDA receptor antagonist for the treatment of neuropathic pain.

The IND submission included a comprehensive data package encompassing preclinical pharmacology, safety, and toxicology studies, including a pivotal neurotoxicity study in Sprague-Dawley rats which showed no evidence of brain lesions or adverse CNS effects-a key distinction from traditional ketamine, which has been associated with NMDA-linked neurotoxicity and the formation of Olney lesions in similar preclinical models. These findings were reinforced by multiple validated neuropathic pain models-including chemotherapy-induced, diabetic, and nerve ligation-induced neuropathy-where Ketamir-2 consistently demonstrated potent analgesic effects and superior efficacy to gabapentin and pregabalin, with reversal of pain sensitivity observed in select models. The IND also incorporated the Company’s Phase 1 readiness data and manufacturing documentation.

MIRA is nearing completion of the Single Ascending Dose (SAD) portion of its international Phase 1 trial at Hadassah Medical Center in Jerusalem, with dose escalation progressing smoothly. The Company is now preparing to initiate the Multiple Ascending Dose (MAD) portion of the study, which will assess the safety, tolerability, and pharmacokinetics of repeated dosing over several days. These data will help inform optimal dosing strategies as MIRA moves toward a Phase 2a study, with the goal of initiating its first U.S.-based efficacy trial in Q4 2025.

“This IND approval validates the strength of our preclinical data and the differentiated pharmacology of Ketamir-2,” said Erez Aminov, Chairman and CEO of MIRA. “We are executing and advancing with precision and speed, and we believe Ketamir-2 may represent one of the most promising non-opioid, non-controlled neuropathic pain treatments in development today.”

Building on Strong Preclinical Evidence

Ketamir-2 has consistently demonstrated robust efficacy and safety across a range of preclinical studies:

• In a chemotherapy-induced neuropathy model, Ketamir-2 achieved near-complete normalization of pain sensitivity and outperformed gabapentin by 60%

• In a validated diabetic neuropathy model induced by a high-fat diet and low-dose streptozotocin (STZ) in rats, Ketamir-2 significantly reduced pain sensitivity, with some animals returning to pre-diabetic baseline sensitivity

• In head-to-head studies using the chronic constriction injury (CCI) model-a widely accepted sciatic nerve ligation model of neuropathic pain-in rats, Ketamir-2 delivered up to 112% greater pain relief than pregabalin and 70% more than gabapentin

• No hyperlocomotion, sedation, or behavioral disturbances were observed, even at high doses

• A comprehensive neurotoxicity study confirmed absence of Olney lesions, a key safety concern in NMDA modulators like ketamine

• Ketamir-2 was shown to cross the blood-brain barrier efficiently, supported by its non-P-gp substrate status and evidence of CNS penetration in preclinical models, supporting oral CNS activity. Preclinical data indicate Ketamir-2 achieves good oral bioavailability-significantly higher than traditional ketamine, which has very low bioavailability when taken orally. This advantage, along with its selective receptor targeting and long-acting metabolite Nor-Ketamir-2, supports its potential as an at-home treatment option.

• Demonstrated antidepressant and anxiolytic-like effects in validated behavioral models, with no dissociative or psychotomimetic side effects

Select findings were recently published in Frontiers in Pharmacology, confirming the molecule’s clean pharmacological profile and positioning Ketamir-2 as a differentiated and scalable alternative to existing treatments. Additional preclinical publications are in progress.

Phase 2a Pathway and Strategic Expansion

With IND clearance secured, MIRA plans to initiate a U.S.-based Phase 2a clinical trial in neuropathic pain in Q4 2025. In parallel, the Company is:

• In discussions with a leading U.S. institution to explore a dedicated trial in chemotherapy-induced peripheral neuropathy (CIPN)

• Evaluating a Phase 2a study in diabetic peripheral neuropathy (DPN), a large, underserved indication with rising prevalence

• Advancing formulation development for topical Ketamir-2 for localized pain applications

Neuropathic Pain: A High-Impact Opportunity Across North America

Neuropathic pain is a widespread and growing concern across North America, with prevalence expected to rise due to aging populations and increasing rates of diabetes and cancer-related treatments. Current therapies often provide only modest relief and are frequently associated with side effects such as sedation, dizziness, weight gain, and dependency risk, limiting their long-term use.

In chemotherapy-induced peripheral neuropathy (CIPN), a significant proportion of patients undergoing treatment experience chronic pain symptoms. Meanwhile, access to IV ketamine remains limited to specialized clinics with long wait times, high cost, and logistical burdens. Ketamir-2’s oral, non-dissociative, and non-opioid profile may help overcome these barriers-offering a more accessible and scalable solution for patients in need.

“Ketamir-2 has demonstrated consistent, potent efficacy across preclinical pain models with a clean safety profile and broad therapeutic potential. The IND approval is a testament to our scientific rigor and may pave the way for meaningful clinical translation,” said Dr. Itzchak Angel, Chief Scientific Advisor at MIRA.

Other Corporate Updates

MIRA also reports that the planned acquisition of SKNY Pharmaceuticals remains on track, with shareholder approval expected in Q3 2025. SKNY-1, the lead asset from SKNY Pharmaceuticals, is a next-generation oral therapy in development for obesity and smoking cessation. In a recent zebrafish model of obesity and craving, SKNY-1 demonstrated up to 30% weight loss, reversal of high-calorie and nicotine-seeking behavior, normalization of appetite hormones, and preservation of muscle mass. Additionally, SKNY-1 reversed anxiety-like behavior in a validated CB1 agonist-induced model, suggesting a favorable neuropsychiatric safety profile. Designed to avoid the psychiatric side effects linked to earlier CB1-targeting drugs and nicotine cessation agents, SKNY-1 could offer a differentiated, well-tolerated alternative to GLP-1s and other interventions. Meanwhile, MIRA-55, the Company’s oral cannabinoid analog, recently showed comparable efficacy to morphine in inflammatory pain models and is under evaluation for further development.

“MIRA is executing at the highest level across all fronts,” added Mr. Aminov. “Ketamir-2’s clinical momentum, the SKNY-1 merger, and advancing MIRA-55 collectively reflect our commitment to delivering innovative, safe, and scalable therapies for patients with limited options. We’re extremely proud of the team’s performance, and we are just getting started.”

About MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company’s pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline.

Cautionary Note Regarding Forward-Looking Statements

This press release and the statements of MIRA’s management related thereto contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA’s current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA’s control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA’s potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA’s programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at www.sec.gov and on MIRA’s website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact:
Helga Moya
info@mirapharma.com
(786) 432-9792

SOURCE: MIRA Pharmaceuticals

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / July 29, 2025 / Europe is reaching a pivotal moment in its industrial transformation. And Systemiq’s latest report, Fossil-Free Plastics: Driving Clean Industrial Leadership in Europe, commissioned by Vioneo, presents a compelling roadmap for reducing carbon emissions from plastic production by accelerating green methanol-to-olefins (MTO) and other fossil-free pathways. It’s a vital piece of the puzzle. But there’s a critical missing layer-one that can’t be filled by chemistry or policy alone.

That missing layer is infrastructure-not of pipes and plants, but of trust and traceability. Because scaling fossil-free plastics isn’t just about making new materials or announcing new targets-it’s about proving what something is, where it came from, and where it ends up. That’s no small feat. But it’s exactly what SMX Ltd. (NASDAQ:SMX) enables. In fact, it does all of that-and more.

The Systemiq report rightly emphasizes accelerating MTO as a viable, cost-competitive drop-in solution for polyethylene and polypropylene. It also identifies four essential drivers to achieve market readiness: early adopter customers, alignment with EU frameworks, harmonized carbon accounting, and smart public funding.

SMX Can Be the Digital Backbone of Circularity

What the report doesn’t mention-but urgently should-is that none of those initiatives can succeed without a verifiable way to track, audit, and certify materials from origin to shelf to end of life. That’s where SMX changes the game. It’s not just a breakthrough-it’s the enabling technology that ties it all together.

And the best part? SMX technology isn’t speculative. It’s operational right now for any company serious about turning circular economy goals into real, measurable action. In this space, SMX may be the only fully scalable platform that connects intention with accountability at the molecular level.

By permanently marking materials, including green methanol-based plastics, SMX enables seamless, end-to-end tracking across the entire supply chain. From production to post-consumer recovery, every link is traceable, transparent, and verifiable.

Imagine a polymer produced from forestry waste, converted through MTO, and encoded with a forensic signature at its origin. That material can then be audited in real time by brand owners, regulators, and recyclers at any stage of its lifecycle. It’s not just about compliance. It’s about building confidence.

And unlike outdated chain-of-custody systems, SMX provides tamper-proof verification. No guesswork. No greenwashing. Just proof.

Meeting the Market Where It’s Headed

Systemiq’s analysis makes one thing clear: even if Europe hits every recycling, reuse, and reduction target, the continent will still need around 28 million tonnes of virgin plastics annually by 2050. The solution isn’t to cut demand-it’s to decouple virgin production from fossil fuels. This means leveraging biomass, captured CO₂, and other renewable resources to meet demand while reducing emissions.

It’s a valid vision. But visions don’t raise capital. Data does.

To unlock the billions in projected investments and demand-side commitments, this transition needs more than ambition. It needs infrastructure investors can trust. SMX delivers that.

Its PCT system lets companies permanently mark, register, and monetize plastic on an open platform-turning environmental claims into certified, tradable assets. Think of it as carbon credits 2.0, only grounded in physical reality. This is especially timely as EU frameworks like the Digital Product Passport (DPP) and Extended Producer Responsibility (EPR) begin requiring exactly this level of verifiable visibility.

Building Trust in a Low-Trust Transition

Let’s not forget: Europe’s shift to fossil-free plastics is as much a credibility challenge as a technical one. Green methanol producers, polymer converters, and brand owners won’t just need to say their materials are sustainable-they’ll need to prove it.

SMX gives them that power. With real-time, tamper-proof traceability, every player in the value chain can operate with confidence. That’s how early-stage investments get de-risked. That’s how high-spec offtake agreements in food packaging and healthcare get signed. And that’s how entire markets get built, not just imagined.

Policy Can’t Carry the Load Alone

Systemiq’s recommendations for demand-side targets, harmonized metrics, and regulatory clarity are spot on. But they’re not enough. Without standardized, verifiable systems to track compliance, even the best-intentioned regulations become bottlenecks instead of catalysts.

Europe has the ambition. MTO and similar innovations have the chemistry. But only SMX offers the infrastructure to make both scalable, provable, and investable.

If Europe wants to lead in fossil-free plastics, it must also lead in how those materials are verified, measured, and trusted. Traceability isn’t optional-it’s foundational. SMX has already built the infrastructure. It’s proven. It’s available. The time for rhetoric is over. With SMX as an ally, time and words are better spent on implementation.

About SMX (Security Matters) Public Limited Company
As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements
The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned PCT; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

Media Contact For This Release:
info@hawkpointmedia.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire

VANCOUVER, BC / ACCESS Newswire / July 29, 2025 / American Critical Minerals Corp. (“American Critical Minerals” or the “Company“) (CSE:KCLI)(OTCQB:APCOF)(Frankfurt:2P3) is pleased to announce that it has engaged Agapito Associates, LLC (“Agapito” or “Agapito Associates“), to define a National Instrument 43-101 (“NI 43-101“) Exploration Target for Lithium at the Company’s Green River Project. Agapito will also update the Company’s existing Technical Report prepared by them and effective September 12, 2012. Such report was focused on the Potash potential of the Green River Project and included a 43-101 Exploration Target for Potash. However, given the emergence of the lithium brines in the Paradox Basin as a major potential source of lithium and the speed and success of development on neighboring projects, it makes sense to now include lithium as a key focus for the Company. Agapito’s work is expected to be completed early in the fourth quarter of 2025. The Company will release the results as received.

Management Commentary

Simon Clarke President & CEO stated, “we are excited to expand our NI 43-101 Technical Report to encompass the large-scale lithium potential across our Project. This has been showcased in recent years by a number of players, but particularly Anson Resources which has a Project contiguous to the North of our Green River Project and a Project adjacent to the South. Anson has advanced both its Projects materially and recently announced a successful Pilot with Koch Technology and an MOU to develop a DLE Demonstration Plant at Green River with POSCO Holdings.

Historic oil and gas drill logs highlight that the same lithium brines are present across our Project Area with similar grades and potential and the advanced development work undertaken by Anson also helps de-risk our Project which is sandwiched between the two Anson Projects. American Critical Minerals is in a unique position as our Project contains both large scale Potash and Lithium targets for what we see as brown-field development moving forward.”

Agapito will carry out a comprehensive set of tasks to evaluate the potential size, grade, and economic viability of lithium-bearing deposits at the Green River Potash and Lithium Project. This work will include a detailed review of existing geological, geophysical, and geochemical data, along with hydrogeological studies focused on the lithium brine target layers-specifically assessing aquifer permeability, storability, and water chemistry. The evaluation will also involve resource modeling and preliminary economic assessments to help refine exploration targets and prioritize areas for further investigation. As part of this effort, Agapito will estimate the brine tonnage and lithium concentration for each of the identified lithium-bearing layers.

About Agapito Associates, LLC

Agapito Associates is partnered with Tiberius Energy Services (“Tiberius“) and Lane Power & Energy Solutions (“Lane“) to form E3 Partners, LLC (“E3“)-a unified team that brings together deep professional expertise and hands-on contracting capabilities. Through this strategic alliance, Agapito now offers a fully integrated approach to well management, combining Agapito’s decades of geotechnical and subsurface engineering experience with Tiberius’s strength in well services and project coordination, and Lane’s proven track record in complex underground construction. As E3, Agapito has the resources and expertise to successfully manage, drill, and abandon each well with efficiency, safety, and regulatory compliance, ensuring every phase of the project is executed to the highest standard.

About American Critical Minerals’ Green River Potash and Lithium Project

The Green River Potash and Lithium Project is situated within Utah’s highly productive Paradox Basin, located 20 miles northwest of Moab, Utah and has significant logistical advantages including close proximity to major rail hubs, airport, roads, water, towns and labour markets. It also benefits from close proximity to the agricultural and industrial heartland of America and numerous potential end-users for its products.

The history of oil and gas production across the Paradox Basin provides geologic data from historic wells across the Project, and the wider Basin, validating and de-risking the potential for high grade potash and large amounts of contained lithium. Wells in and around the project reported lithium up to 500 ppm, bromine up to 6,100 ppm and boron up to 1,260 ppm (Gilbride & Santos, 2012). This data is reinforced by nearby potash production and the advanced stage of neighbouring lithium projects. The Paradox Basin is believed to contain up to 56 billion tonnes of lithium brines, potentially the largest such resource in US (Source: Anson Fastmarkets Presentation – https://wcsecure.weblink.com.au/pdf/ASN/02823465.pdf) The Company also has a 43-101 Exploration Target of 600 million to 1 billion tonnes of sylvinite (the most important source for the production of potash in North America) with average grades ranging from 19% to 29% KCL.**

The Company holds a 100% interest in eleven State of Utah (“SITLA“) mineral and minerals salt leases covering approximately 7,050 acres, 1,094 federal lithium brine claims (BLM Placer Claims) covering 21,150 acres, and 11 federal (BLM) potash prospecting permits covering approximately 25,480 acres. Through these leases, permits and claims the Company has the ability to explore for potash, lithium and potential by-products across the entire Green River Project (approx. 32,530 acres). The Company is authorized to drill a total of 7 exploratory drill holes across the Project (pending bonding the recently approved 4 drill holes).

Intrepid Potash, Inc. is America’s largest potash company and only U.S. domestic potash producer and currently produces potash from its nearby Moab Solution Mine, which the Company believes provides strong evidence of stratigraphic continuity within this part of the Paradox Basin (www.intrepidpotash.com). Anson Resources Ltd. has advanced lithium development projects contiguous to the northern boundary of our Green River Project and neighbouring to the south. Anson has a large initial resource, robust definitive feasibility study and has recently completed successful piloting operations through its partnership with Koch Technology Solutions, as well as an offtake agreement with LG Energy Solution. The Anson exploration targets encompass the combined Mississippian Leadville Formation and the Pennsylvanian Paradox Formation brine-bearing clastic layers, which also underlie American Critical Minerals’ entire project area (www.ansonresources.com)*.

In 2022, the U.S. imported approx. 96.5% of its annual potash requirements with domestic producers receiving a higher sales price due to proximity to market (intrepidpotash.com/ August 15, 2024, Investor Presentation). In March 2024, the US Senate introduced a bill to include key fertilizers and potash on the US Department of Interior list of Critical Minerals which already includes lithium. Recent market estimates suggest that the global potash market is over US$50 billion annually and growing at a compound annual growth rate (“CAGR”) of close to 5%. Annual lithium demand is now estimated to be over 1 million tonnes globally and continuing to grow rapidly.***

Qualified Person

The Technical content of this news release has been reviewed and approved by Dean Besserer, P.Geo., the Chief Operations Officer (“COO“) of the Company and a qualified person for the purposes of NI 43-101.

On behalf of the Board of Directors

Simon Clarke, President & CEO

Contact: (604)-551-9665

*American Critical Minerals’ management cautions that results or discoveries on properties in proximity to the American Critical Minerals’ properties may not necessarily be indicative of the presence of mineralization on the Company’s properties.

**A report titled “NI 43-101 Technical Report – Green River Potash Project, Grand County, Utah, USA”, prepared by Agapito Associates Inc., and dated effective September 12, 2012, quantifies the Green River Potash Project’s potash exploration potential in the form of a NI 43-101 Exploration Target. The Exploration Target estimate was prepared in accordance with the National Instrument 43-101 -Standards of Disclosure for Mineral Projects (“NI 43-101“). It should be noted that Exploration Targets are conceptual in nature and there has been insufficient exploration to define them as Mineral Resources, and, while reasonable potential may exist, it is uncertain whether further exploration will result in the determination of a Mineral Resource under NI 43-101. The Exploration Target stated in the Agapito Report is not being reported as part of any Mineral Resource or Mineral Reserve. A copy of the report can be accessed on the corporate website for the Company: www.acmineralscorp.com.

***United States Geological Survey, Mineral Commodity Summaries, January 2024 (https://pubs.usgs.gov/periodicals/mcs2024/mcs2024-potash.pdf).

Cautionary Statements Regarding Forward Looking Information

This news release contains forward-looking information within the meaning of applicable securities legislation. Forward-looking information is typically identified by words such as: believe, uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Important factors that could cause actual results to differ from this forward-looking information include those described under the heading “Risks and Uncertainties” in the Company’s most recently filed MD&A. The Company does not intend, and expressly disclaims any obligation to, update or revise the forward-looking information contained in this news release, except as required by law. Readers are cautioned not to place undue reliance on forward-looking expect, anticipate, intend, estimate, postulate and similar expressions, or are those, which, by their nature, refer to future events. Such statements include, without limitation, statements regarding future confirmation drilling and its intended outcomes. Although the Company believes that such statements are reasonable, it can give no assurances that such expectations will prove to be correct. All such forward-looking information is based on certain assumptions and analyses made by the Company in light of their experience and perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. This information, however, is subject to a variety of risks and information.

SOURCE: American Critical Minerals Corp.

View the original press release on ACCESS Newswire

Biolog, a leading provider of microbial identification and phenotypic characterization tools and services, announced today that both its anaerobic media and anaerobic chambers have received CE marking, clearing the way for broader international use

HAYWARD, CALIFORNIA / ACCESS Newswire / July 29, 2025 / Biolog, a leading provider of microbial identification and phenotypic characterization tools and services, announced today that both its anaerobic media and anaerobic chambers have received CE marking, clearing the way for broader international use. The media and chambers were part of Biolog’s acquisition of Anaerobe Systems earlier this year with the objective of bringing class-leading tools for microbiology to the rapidly growing clinical, microbiome, and agricultural markets.

Today, Biolog’s TruPRAS™ media is the only commercial media manufactured under true pre-reduced, anaerobically sterilized conditions, preventing the formation of harmful byproducts that can be toxic to anaerobic organisms. This line of media products, which has been approved for In Vitro Diagnostic (IVD) use by the USA FDA for years, has now also achieved CE marking under the requirements of the EU IVDR regulation 2017/746. With zero recalls or field actions throughout their extensive history, these products enable transport of specimens and growth of fastidious anaerobes that play important roles in disease pathology – supporting clinical diagnostics in medical laboratories.

“The IVDR/CE mark is a major milestone that recognizes the high standard of our anaerobic media and its value in supporting critical diagnostic workflows,” said Robert Wicke, CEO at Biolog. “We’re proud that clinical labs throughout Europe can now benefit from the same reliable performance that researchers and clinicians in the U.S. have trusted for decades.”

Biolog’s anaerobic chambers have also received the CE mark, affirming their safety and performance for use in any research settings throughout the world. With unique InstaSleeve™ technology, these ergonomic, gloveless chambers offer superior processing dexterity while working in a fully anaerobic environment and are a preferred tool for microbiologists in both clinical and academic settings. In addition, Biolog is releasing an upgrade to enable hypoxic or microaerophilic conditions in the same chamber, for organisms that require specific, low concentrations of oxygen to thrive.

“This dual achievement reinforces Biolog’s commitment to advancing global access to high-quality tools for anaerobic microbiology,” said Wicke. “Whether you’re working with challenging clinical isolates or conducting fundamental research, Biolog now provides dependable CE-marked solutions that meet your needs.”

About Biolog

Biolog offers tools, services, and support for comprehensive cellular characterization and multi-omic identification of bacteria, yeast, and fungi. Our products also enable phenotypic profiling of microbial and mammalian cells for a range of applications, including supporting the culture of fastidious anaerobes with our line of gloveless chambers and pre-reduced media. Learn more at biolog.com

Contact Information

John Proctor, Ph.D.
CCO
jproctor@biolog.com
(408)306-0414

SOURCE: Biolog, Inc.

View the original press release on ACCESS Newswire